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MaThis paper provides practical guidance on the fundamentals of design for major randomized controlled trials. Topics
covered include the choice of patients, choice of treatment and control groups, choice of primary and secondary
endpoints, methods of randomization, appropriate use of blinding, and determination of trial size. Insights are made with
reference to contemporary major trials in cardiology. (J Am Coll Cardiol 2015;66:2757–66)
© 2015 by the American College of Cardiology Foundation.T he properly designed randomized controlledtrial is recognized as providing the highestlevel of evidence in determining guidelines
for therapeutic practice (1). However, numerous
pitfalls in trial design may occur, which, if succumbed
to, may seriously impair the reliability of or conﬁ-
dence in the results. In this paper, we review the
key features that determine whether a trial’s design
is “up to scratch.” These fundamentals include:
selection of patients, treatments, and outcomes;
randomization methods; appropriate blinding; and
determination of trial size, which are summarized in
the Central Illustration. Of course, one ﬁrst has to pro-
pose a relevant clinical question for which true equi-
poise exists.
Our focus is on major, pivotal (phase III) trials that
are intended to directly inﬂuence clinical practice,
and throughout we bring the issues to life with topical
examples from recent cardiology trials. Our underly-
ing intent is to elucidate matters of trial design that
should be considered and clearly documented in a
study protocol (2,3). Once the study protocol is
ﬁnalized, it is good practice to register the trial on a
website (prior to patient enrollment) and to make the
protocol readily available. The core goals are to plan
each trial so that it will achieve unbiased conclusions
for treatment comparisons of direct public healthm the *Department of Medical Statistics, London School of Hygiene and T
olumbia University Medical Center, New York-Presbyterian Hospital, and
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nuscript received September 24, 2015; revised manuscript received Octobrelevance that are both clinically meaningful and
statistically precise. It is fundamentally important to
differentiate a statistically signiﬁcant difference from
a clinically meaningful difference. Very large studies
may sometimes result in small, statistically signiﬁ-
cant differences in outcomes that have little or no
clinical relevance. It is, of course, also essential that
the trial can be successfully completed. That is, from
ethical, scientiﬁc, organizational, and funding
standpoints, the protocol is deliverable. This prag-
matism underpins all that follows here.
CHOICE OF PATIENTS AND CENTERS
The delineation of precise eligibility criteria is
important in determining the population of patients
to which the trial ﬁndings can be extrapolated (3).
Setting the criteria too speciﬁcally can inhibit suc-
cessful patient recruitment and restrict generaliz-
ability, whereas unduly broad entry criteria may
dilute the opportunity to identify a treatment effect
in a speciﬁc population.
In acute coronary syndromes (ACS), the PLATO
(Platelet Inhibition and Patient Outcomes) trial of
ticagrelor versus clopidogrel studied a broad popula-
tion: patients with ACS with or without ST-segment
elevation and treated with or without invasiveropical Medicine, London, United Kingdom; and the
the Cardiovascular Research Foundation, New York,
nt to the contents of this paper to disclose.
er 23, 2015, accepted October 25, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome
CV = cardiovascular
MI = myocardial infarction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
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AMI (Harmonizing Outcomes with Revascu-
larization and Stents in Acute Myocardial
Infarction) trial compared anticoagulation
regimens only in patients undergoing primary
percutaneous coronary intervention (PCI) in
acute myocardial infarction (MI) (5). This was
appropriate, as the ACUITY (Acute Catheteri-
zation and Urgent Intervention Triage Strat-
egy) trial had already studied bivalirudin in
ACS patients with high-risk unstable angina ornon–ST-segment elevationMI (6). As the prognosis and
treatment pathways for patients with ACS with and
without ST-segment elevation are quite different, it is
advisable to avoid pooling these 2 groups in a single
trial design unless each cohort is separately powered
for safety and efﬁcacy.
In chronic heart failure, the CHARM (Candesartan in
Heart Failure Assessment of Reduction in Mortality
and Morbidity) trial of candesartan had broad entry
criteria with no entry ejection fraction restriction,
although the investigators recognized that patients
with preserved left ventricular systolic function
should be interpreted as a separate stratum: CHARM
Preserved (7,8). In contrast, the RALES (Randomized
Aldactone Evaluation Study) trial of spironolactone
focused on high-risk patients (history of New York
Heart Association functional class IV and ejection
fraction #35%). This facilitated using all-cause mor-
tality as a realistic primary endpoint, but restricted the
generalizability of the trial ﬁndings (9). Alternatively,
some trials recruit only high-risk patients to achieve a
sufﬁcient number of outcome events, for example,
SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients with Diabetes Melli-
tus-Thrombolysis In Myocardial Infarction 53) and
other cardiovascular (CV) safety trials in diabetes (10).
Nearly all major trials in cardiology are multi-
center trials, and many have a global recruitment
strategy. The occasional exception happens (e.g.,
the single-center TAPAS [Thrombus Aspiration
during Percutaneous Coronary Intervention in Acute
Myocardial Infarction] and HEAT-PPCI [How Effective
are Antithrombotic Therapies in Primary Percutaneous
Coronary Intervention] trials in ST-segment elevation
myocardial infarction [STEMI] patients) (11,12), but
then their generalizability is uncertain. The results of
single-center trials may be unique to the speciﬁc
practices and techniques used at that institution,
adequate masking and absence of independent moni-
toring and core laboratories may be issues, resource
commitment is often less than in multicenter trials,
and treatment effect sizes can sometimes be at odds
with multicenter investigations.However, global trials raise other issues: problems
of ensuring trial quality in all countries; issues with
center-to-center variability and training; easier
recruitment in certain regions (e.g., Eastern Europe),
which affects the distribution of geographic repre-
sentation; and concerns over geographic heterogene-
ity in treatment effect, as occurred in the TOPCAT
(Treatment of Preserved Cardiac Function Heart
Failure With an Aldosterone Antagonist) trial of spi-
ronolactone in preserved cardiac function heart failure
(Figure 1) (13). Nonetheless, large-scale multicenter
trials are preferable to single-center studies, with the
understanding that the results apply to the geogra-
phies and practices of the participants. Secondary
analysis should be undertaken to ensure that there are
no major geographic disparities in the results (14).
CHOICE OF TREATMENTS AND
CONTROL GROUPS
In drug trials, usually the new treatment has 1
speciﬁc dose regimen that is selected on the basis of
earlier research investigating the agent’s safety
proﬁle, and surrogate endpoints are often used to
evaluate efﬁcacy. Occasionally, a major trial proceeds
with 2 different doses of the new drug, for example,
RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) in atrial ﬁbrillation and
PEGASUS-TIMI 54 (Prevention of Cardiovascular
Events in Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of
Aspirin-Thrombolysis In Myocardial Infarction 54) in
the post-MI setting (15,16). If the increase in trial size
necessitated by 2 experimental drug regimens is
achievable (with appropriate adjustments to preserve
alpha), examining different drug doses (or, occa-
sionally, even different experimental treatments) is,
in principle, a valuable design option, although con-
troversies can ensue in interpretation of ﬁndings.
The appropriate choice of control group is crucial
in trial design (17). Many opt for a placebo control,
whereby the new drug or placebo is assigned on top of
current therapeutic practice, for example, CHARM
and SHIFT (Systolic Heart Failure Treatment with the
If Inhibitor Ivabradine Trial) (assessing ivabradine) in
chronic heart failure (7,18). This is common for reg-
ulatory trials; evidence for Food and Drug Adminis-
tration approval can be straightforward, but in an
advancing ﬁeld such as heart failure, this means that
patients face a growing polypharmacy with little ev-
idence that any drugs get withdrawn from routine use
(19).
Opting for an active comparator poses additional
challenges. For example, in the PARADIGM-HF
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2759(Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity
in Heart Failure) trial in heart failure, which
compared LCZ696 with enalapril (20), the consequent
superiority of LCZ696 is liable to have a far greater
effect than if a placebo control had been chosen.
Others will choose an active comparator to demon-
strate noninferiority in efﬁcacy, anticipating other
beneﬁts (e.g., safety). An example is the ACUITY trial
in ACS, which compared bivalirudin with heparin plus
a glycoprotein IIb/IIIa inhibitor (noninferior rates of
composite adverse ischemic events with reduced
major bleeding) (6). A placebo control would be un-
ethical in many such scenarios. We review non-
inferiority trials in next week’s paper.
Another option is to have a third combination
treatment arm, new drug þ active comparator, as was
done in the VALIANT (Valsartan in Acute Myocardial
Infarction) trial of valsartan versus enalapril versus
both in MI with complications (21). In this instance,
the combination demonstrated an excess of adverse
events without improving survival, a warning that
combination arms need careful preparatory study to
see if their safety proﬁles are acceptable.
Another consideration for chronic disease trials is
whether to have a run-in period prior to randomiza-
tion on the new drug, the comparator, or both in
sequence (as in PARADIGM-HF) (20). In principle, thishelps to conﬁne enrollment to patients who can
tolerate both treatments, resulting in greater adher-
ence, but care is needed to ensure that a fair and
relevant treatment comparison is not compromised.
Trials with a run-in period tend to result in better
drug adherence and tolerability than would otherwise
occur. For instance, if a trial of ticagrelor had a run-in
period, patients experiencing dyspnea in the short-
term would likely be excluded, thereby under-
reporting dyspnea in the consequent randomized
comparison.
Trials comparing radically different strategies,
such as PCI versus coronary artery bypass graft, face
unique challenges, which are discussed in the next
paper in this series.
CHOICE OF PRIMARY AND
SECONDARY OUTCOMES
Most major trials in cardiology focus attention on
disease event outcomes. Treatment effects on
potential surrogate endpoints (22) and biomarkers in
earlier-phase trials can be a useful motivation and
help determine drug dose, but pivotal trials typi-
cally require clear evidence of patient beneﬁt using
clinical endpoints if they are to inﬂuence treatment
practice. Nonetheless, many drugs (and some
devices) are approved on the basis of surrogate
FIGURE 1 Geographic Disparities in the TOPCAT Trial’s Results for the
Primary Endpoint (Cardiovascular Death and Heart Failure Hospitalization)
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TABLE 1 Key Issues
Considerations
Statistical power
Selecting components
of the composite
Evaluating treatment
effect
Analysis considerations
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2760endpoints (e.g., blood pressure or glucose control).
Given the cost and complexity of pivotal randomized
trials, there is increasing interest in considering sur-
rogates as pivotal trial endpoints, but the criteria for
true surrogacy are difﬁcult, although not impossible,
to achieve (23). For example, angiographic late loss
after coronary stent implantations has been demon-
strated to be a surrogate for ischemia-driven target
lesion revascularization (24).
Although selection of which clinical events to
collect follow-up data on may be straightforward,Regarding Composite Endpoints
Discussion
For adequate power, trials with a single endpoint may be too large
to be practical.
Including several endpoints increases event frequency and may
increase power.
A single endpoint may not fully document treatment effect.
Composite endpoint captures several clinical aspects.
Choose components so overall effect is meaningful.
Interpretation can be difﬁcult:
 Components may differ in clinical importance.
 Effect of treatment may vary across components.
It is best to have separate safety and efﬁcacy endpoints.
Emphasis usually on time to ﬁrst event, which is often less serious
(e.g., hospitalization) than subsequent events (e.g., death).
Always show results for each separate component.
Methods exist for repeat events and for competing risks, but
complexity is a challenge.
Win ratio method prioritizes events of greater clinical importance.precise deﬁnitions are needed in the study protocol.
Furthermore, many trials have an independent
events adjudication committee (25) that is blinded
to treatment assignment, a potentially important
quality control measure to ensure a greater consis-
tency of event arbitration than can be achieved by
relying on individual investigators.
An important challenge is to deﬁne the primary
endpoint for the trial (26). In trials of high-risk pa-
tients, such as the PARTNER (Placement of Aortic
Transcatheter Valves) trials of transaortic valve
replacement (27), all-cause death is the primary
outcome. However, for most major trials, a composite
primary endpoint (26) comprising several nonfatal
events along with mortality is chosen; no 1 type of
event adequately captures the treatment effect, and
such a composite has the potential to enhance
statistical power by the greater frequency of patients
experiencing at least 1 component of the composite
during follow-up (Table 1).
However, what events should contribute to a
composite primary endpoint? This depends on the
disease and treatments being studied. In ACS and
diabetes CV safety trials, the usual composite is CV
death, MI, and stroke. Some are tempted to add in
extra components, for example, including unstable
angina or ischemia-driven revascularization into a
broader major adverse CV events composite. This
boosts the numbers of events but dilutes the effect
and meaning of the composite. For instance, the most
frequent (and often least clinically relevant)
component tends to be the driver of event rates (e.g.,
enzymatic MIs or revascularization in ACS trials).
In chronic heart failure, the standard composite
primary endpoint is CV death and hospitalization for
heart failure. The weakness here is that it emphasizes
the ﬁrst hospitalization and ignores any subsequent
hospitalizations or death thereafter. Greater insight
and enhanced statistical power may be achieved by
a primary endpoint analysis that incorporates both
repeat hospitalizations for heart failure and CV death
(28), as in the ongoing PARAGON-HF (Efﬁcacy and
Safety of LCZ696 Compared to Valsartan, on
Morbidity and Mortality in Heart Failure Patients
With Preserved Ejection Fraction) trial (29).
Several options exist for the analysis of repeat
events (e.g., hospitalizations) in chronic disease (e.g.,
heart failure) trials and are illustrated in reanalyses of
the CHARM and CORONA (Controlled Rosuvastatin
Multinational Trial in Heart Failure) trials (28,30). It is
important to recognize that repeat events within a
patient are not independent. For example, a few
patients will have many hospitalizations, whereas
many will have none at all. The negative binomial
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per treatment and hence a rate ratio (and its conﬁ-
dence interval). One complexity is the competing risk
of mortality: patients often have high event rates
prior to death, but their follow-up is then informa-
tively censored. Joint frailty models can simulta-
neously estimate both hospitalization and mortality
risks; the challenge is how to make such statistical
complexity comprehensible to readers of trial reports
with repeat events data.
Novel methods of handling composite endpoints
are of value when the components vary in their clinical
severity and importance. The least serious component
may tend to occur earlier (and more frequently), and
thus is afforded undue priority in a conventional
analysis. These novel methods, for example, the
Finkelstein-Schoenfeld method or the win ratio,
invert the priorities to match with clinical severity (31–
33). The principle behind the win ratio method is that
one compares every possible pair of patients on the
new treatment and the standard treatment. First, the
“new” patient is declared the winner or loser if they
did better or worse on the most serious outcome (e.g.,
who lived longer). If neither died, then you decide the
winner or loser on the basis of who had the next most
serious outcome (e.g., hospitalization) ﬁrst and so on,
if there are more (less-serious) events to help deter-
mine who did worse. Then, across all pairs, one notes
the number of winners and number of losers for the
new treatment (ignoring any “tied” pairs who had no
relevant events); the win ratio is the former number
divided by the latter. This concept can be extended to
include nonevent outcomes (e.g., ejection fraction)
as a “tie-breaker” in patients who are otherwise
event-free (34).
Another challenge is how to incorporate pre-
deﬁned safety concerns, for example, major bleeding
in antiplatelet and anticoagulant drug trials, into the
overall outcome priorities. Some trials (e.g., ACUITY
and OPTIMIZE [Optimized Duration of Clopidogrel
Therapy Following Treatment With the Zotarolimus-
Eluting Stent in Real-World Clinical Practice] [6,35]),
have extended major adverse CV events to net
adverse clinical events by adding major bleeding as an
extra component of the primary composite outcome
(26). If the included safety and efﬁcacy components
are weighted similarly in terms of their clinical
importance, such an endpoint may reﬂect the overall
net clinical beneﬁt to the patient of the therapies
being evaluated. However, if adequate power is
present, it may be more desirable to evaluate efﬁcacy
and safety separately as coprimary endpoints. For
example, major bleeding was pre-deﬁned as the pri-
mary safety outcome in the HORIZONS-AMI trial (5).In general, efforts to collect quality data on
potential safety concerns are important. Although
Medical Dictionary for Regulatory Activities coding of
adverse events and serious adverse events is well
established (36), the process has its limitations. Thus,
if prior insight into which safety concerns may plau-
sibly arise is available, speciﬁc extra reporting pro-
cedures may be undertaken for such events.
Having deﬁned the primary endpoint, it is impor-
tant to then provide a list of secondary endpoints in the
protocol, along with any pre-deﬁned priorities among
them. Speciﬁcally, the separate components of the
primary endpoint should be included here. For regu-
latory trials, interest focuses on how to interpret
secondary endpoint data should the primary be “pos-
itive,” that is, can one extend the label to include any
positive secondary endpoints? Across a multiplicity of
outcomes there are 2 options in this regard. First, one
can list a set of secondary endpoints in order of prior-
ity, so that one can proceed down that list when results
are known, counting all in sequence as positive until 1
fails to reach statistical signiﬁcance (hierarchical
testing). Alternatively, one can pre-declare, on equal
terms, a speciﬁc set of secondary outcomes and use a
statistical correction for multiplicity (e.g., the Hoch-
berg procedure [37]) in determining which endpoints
meet criteria as “positive.” If a method to control for
multiplicity was not pre-speciﬁed, the data with con-
ﬁdence intervals should just be presented and clearly
identiﬁed as secondary outcomes. Although the im-
plications from such secondary endpoints should
usually be considered exploratory and hypothesis
generating, they still may provide a persuasive level of
evidence if highly positive (e.g., p < 0.001).
Because patient-centered outcomes and economic
evaluations are of increasing importance, secondary
outcomes may also include quality of life, patient
preferences, and resource utilization data.
METHODS OF RANDOMIZATION
The justiﬁcation for randomization and the problems
in interpreting nonrandomized treatment compari-
sons are well known (38,39). Herein, we discuss the
actual methods of setting up and delivering random
allocation of patients to treatments (Table 2) (40).
There are 3 key elements: 1) the statistical methods
used to set up the sequence of randomized treatment
assignments; 2) the practical means by which the
investigator assigns each randomized treatment; and
3) ensuring that patient eligibility, investigator
agreements, and informed patient consent are all in
place before randomization. Informed consent is a
vital component of ethical trial conduct, but its
TABLE 2 Key Issues Regarding Randomization Methods
Considerations Discussion
Allocation concealment Ensure treatment assignment cannot be predicted in advance of
patient entry.
Double-blinding Patients, investigators, and those evaluating outcome remain
unaware of assigned treatment after randomization.
Single-blinding Investigators (and possibly patients) are aware of the assigned
treatment, whereas those evaluating outcomes remain
blinded.
Superior to an unblinded design, but introduces greater
opportunities for bias than a double-blind design.
Methods of randomization
Simple randomization Like coin tossing, with no connection between allocations.
May lead to treatment imbalance in numbers or key patient
factors.
Random permuted
blocks
Treatment numbers are equal after each block of patients.
Order of treatments within each block is random.
Block sizes may vary to avoid predictability if trial not
double-blinded.
Stratiﬁcation Aims to ensure balance for key patient factors across treatment
groups.
Each combination of factors (e.g., center and sex) has its own
random permuted blocks.
Must avoid overstratiﬁcation (e.g., 4 binary factors ¼ 16 strata),
which may introduce imbalances.
Minimization A dynamic approach.
Each treatment allocation is done to achieve the best balance
across several patient factors.
Unequal randomization Can allocate more patients on new treatment (e.g., 2:1 ratio).
Increases knowledge of new treatment and may enhance
investigator/patient enthusiasm.
Requires more patients.
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statistical paper. We do note, however, that there are
special challenges to obtaining consent in an emer-
gency setting, for example, primary PCI in STEMI
patients.
A central tenet is that the investigator cannot pre-
dict the assignment in advance because that could
bias the choice of the next patient to be randomized.
The CONSORT guidelines state that a trial publication
should document these randomization methods (41).
For example, the MATRIX (Minimizing Adverse Hae-
morrhagic Events by Transradial Access Site and
Systemic Implementation of AngioX) trial stated:
“before start of angiography, patients were centrally
assigned (1:1) to radial or femoral access.using a
web-based system to ensure adequate concealment of
allocation. The randomized sequence was computer
generated, blocked and stratiﬁed by.use of ticagrelor
or prasugrel, type of ACS (STEMI or non-STEMI) and
anticipated use of immediate PCI” (42). Thus,
MATRIX used 1 of the most common approaches: a
web-based allocation system and random permuted
blocks within strata, with 2  2  2 ¼ 8 strata in this
instance. What is not stated here is the number of
patients in each randomized block: commonly this is
set at 4 (2 per treatment) or 6 (3 per treatment) in a
random order. Because MATRIX is an “open” study,blocks of varying size would be recommended to
avoid prediction of some assignments in advance,
whereas this consideration is less important for blin-
ded trials.
For the CURRENT-OASIS 7 (Clopidogrel and Aspirin
Optimal Dose Usage to Reduce Recurrent Events–
Seventh Organization to Assess Strategies in Ischemic
Syndromes) trial, a 24-h computerized, central auto-
mated voice-response system with permuted block
randomization stratiﬁed by center was used (43).
Note the need for continuous day and night
randomization in an acute setting.
These 2 examples, 1 stratifying by 3 patient factors
(but not center) and the other stratifying by center
only, reﬂect the diversity of approaches to stratifying
randomization. Indeed, some trials (e.g., CHARM in
chronic heart failure [7]) have just a simple random-
ization list with permuted blocks. So, why stratify at
all? Stratiﬁcation offers insurance that for a key pa-
tient feature, a serious imbalance between treatment
groups will not arise by chance. However, for large,
pivotal trials, this becomes very unlikely, and if it
does occur, it may be accounted for in a covariate-
adjusted analysis. In addition, trialists often have
difﬁculty agreeing on the choice of stratiﬁcation
variables, and the gain in statistical efﬁciency by
stratiﬁcation is negligible. However, showing near-
perfect balance in treatment groups for key baseline
variables is a convenient bonus of stratiﬁcation.
An alternative method of achieving balance across 2
or more baseline features is called minimization (44).
Minimization is a dynamic approach (randomization
lists are not prepared in advance) whereby as each
patient enters the trial, a computerized algorithm
determines which treatment assignment would ach-
ieve the better overall balance across multiple patient
characteristics. That treatment is then assigned, or to
preserve a chance element, it is assigned with a high
probability (e.g., 0.75). For example, the TITRe2
(Transfusion Indication Threshold Reduction) trial of
liberal versus restrictive transfusion after cardiac
surgery “used cohort minimization to balance
assignments according to center and type of surgery”
(45). Whatever method is chosen, what is more
important than stratiﬁcation is ensuring that
randomization is carried out in a rigorous manner.
Sometimes an unequal randomization is used, for
example, with a 2:1 or 3:2 ratio in favor of the new
treatment (46). This has 2 possible advantages: it in-
creases information on the new treatment (e.g., to
allay safety concerns) and may also stimulate greater
enthusiasm by investigators and patients knowing
they have more than a 50:50 chance of getting the
new treatment. For instance, the SYMPLICITY-HTN 3
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renal denervation versus a shamprocedure in resistant
hypertension had a 2:1 randomization ratio, whereas
the HORIZONS-AMI trial in primary PCI had a 3:1 ratio
of drug-eluting versus bare-metal stents (5,47). But,
there is a loss of statistical power with unequal
randomization. For example, for 3:2, 2:1, and 3:1 ratios,
the total number of patients needs to increase by 4.2%,
12.5%, and 33.3%, respectively, to preserve the same
power as a trial with equal randomization.
BLINDING
It is standard practice for drug trials to be double-
blind: that is, the patients and those responsible for
their treatment and follow-up evaluation do not
know which randomized treatment they are assigned
(48,49). This is the optimal way to ensure that any
potential inﬂuence that awareness of treatment
might have on patient perceptions, patient manage-
ment, and evaluation of endpoints is avoided.
So, what are we tomake of trials that are not double-
blinded? For instance, the 3-arm RE-LY trial in atrial
ﬁbrillation compared 2 ﬁxed doses of dabigatran in a
blinded manner with open-label use of warfarin (15).
Does this bias the comparison with warfarin? Having
all primary and secondary outcome events adjudicated
by an independent group that was centrally blinded
helps reduce bias, but we are still reliant on unblinded
patients and investigators to fairly report relevant
events. Other similar trials, for example, the ARIS-
TOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trial of
apixaban versus warfarin, were double-blinded with
the consequent complexity of carrying out repeat in-
ternational normalized ratio testing on all patients,
including those not on warfarin (50). Which of these
approaches is better is open to debate.
Of course, many trials of devices and alternative
treatment strategies cannot possibly be double-
blinded. For instance, the MATRIX trial of radial
versus femoral access for ACS patients undergoing
invasive management inevitably had patients and
treating physicians who were aware of their random-
ized assignment, but outcome assessors were masked
(blinded) (42). Such a PROBE (Prospective Random-
ized Open Blinded Endpoint) design is commonly used
(51), but many researchers believe that the data
obtained is less reliable than in a double-blind study.
Blinding becomes particularly important when the
primary endpoint is not on the basis of “hard” clinical
events (with objective deﬁnitions), but on softer
endpoints, such as quality of life indicators or a mea-
surement such as blood pressure. The SYMPLICITYHTN-3 trial in resistant hypertension is an important
illustration of the value of comparing a device (renal
denervation) with a sham procedure. Both the patients
and the blood-pressure assessors were unaware of the
study group assignments (47). In prior unblinded and
uncontrolled studies, marked blood pressure lowering
was attributed to renal denervation. In contrast, in
the sham-controlled randomized trial, comparable
reductions in blood pressure were noted in the treat-
ment and control groups, suggesting a substantial
placebo effect with some regression to the mean (52).
The neutral ﬁnding of this trial, the ﬁrst objective,
unbiased evaluation of renal denervation, has impor-
tantly affected future trial design considerations for
medical devices in general.
TRIAL SIZE
A key role of statistical reasoning in trial design is the
provision of power calculations to determine the
required trial size (53). Focusing on the trial’s primary
endpoint, one needs to specify the expected event rate
in the control group, the magnitude of treatment
effect that the trial is required to detect (the alterna-
tive hypothesis), and the degree of certainty that such
detection should occur (the statistical power [1 – (risk
of a type II error [b])] and the signiﬁcance level that
qualiﬁes as “detected” (the risk of a type I error [a]).
For instance, in the CHAMPION (Cangrelor versus
Standard Therapy to Achieve Optimal Management of
Platelet Inhibition) PHOENIX trial in patients under-
going PCI, the composite primary endpoint was death,
MI, ischemia-driven revascularization, and stent
thrombosis within 48 h. The investigators planned for
a difference of 5.1% in patients treatedwith clopidogrel
versus 3.9% in patients treated with cangrelor (a 24.5%
relative risk reduction) to be detected with 85% power
and type I error of 0.05. This required a total of 10,900
randomized patients (5,450/group). They actually
recruited 11,145 patients, and the observed difference
was in fact 5.9% versus 4.7% (p ¼ 0.005) (54).
Note the large sample size that was required. Had
the trial planners hypothesized an unrealistic 50%
relative risk reduction with 80% power, the required
trial size would have been reduced to 1,780 patients.
With observed rates of 5.9% versus 4.7%, the p value
would have been 0.25, well short of statistical sig-
niﬁcance. Fortunately, such overoptimistic planning
is becoming less common nowadays in major CV tri-
als, although this requires commitment to relatively
large trials with modestly realistic, but still clinically
important, expectations of treatment beneﬁt.
For chronic disease trials, sample size determina-
tion involves considering length of follow-up as well
FIGURE 2 Total Number of Primary Events Needed to Detect a Speciﬁc True
Hazard Ratio as Statistically Signiﬁcant (a ¼ 0.05)
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trial in chronic heart failure was planned to recruit
8,000 patients with a mean 34 months of follow-up.
For the composite primary endpoint of heart failure
hospitalization and CV death, they anticipated an
annual event rate of 14.5% on enalapril and had 97%
power to detect a 15% relative risk reduction on
LCZ696, with type I error of 0.05. Why set the power
so high? They wanted good statistical power (80%) to
also detect the same relative risk reduction in the
secondary endpoint of CV death alone. A wise choice,
in fact, because the published trial results showed
marked treatment beneﬁts for both outcomes (20).
A cynical view of statistical power calculations is
that people “juggle with the numbers” until they get
the sample size they always wanted (or could afford).
There is an element of truth to this: there are practical
limits on what is achievable patient recruitment.
Hence, some compromise is needed in not making the
target so difﬁcult as to put the consequent number of
patients out of range for a real world study.
So, how can we “play with the numbers” while
preserving scientiﬁc integrity? Take CHAMPION
PHOENIX as an example (54), and consider varying
the parameters that feed into the calculations:
1. Control group event-rate. If one were to double the
anticipated 5.1% rate to 10.2%, while keeping the
same relative risk reduction and power, one could
halve the required number of patients. But, thiswould be an artiﬁcial deception unless recruitment
was restricted to very high-risk patients, an unre-
alistic option in this case.
2. Alternative hypothesis. The required number of
patients is inversely proportional to the square of
the declared absolute treatment difference. So if
one increased this difference from 5.1% (control) 
3.9% (treatment) ¼ 1.2%, to 5.1%  2.7% ¼ 2.4%,
one would only need less than one-quarter of the
patients, that is, 2,400 rather than 10,900. In
contrast, halving the difference to a mere 0.6%
takes the sample size to a staggering 46,300 pa-
tients. The declared 1.2% difference was a realistic
compromise.
3. Power. There is nothing magical about the chosen
power. The greater the power, the larger the
required patient numbers (but the smaller the
likelihood of failing to detect a difference that is
truly present). A common choice is 90% power; it
carries a reasonable sense of guarantee that one
would be unlucky (10% chance) to miss out on
detecting the speciﬁed treatment difference, if it
were true. If one reduces the power to 85% or 80%,
then trial size can be reduced by 14% and 25%,
respectively. Reducing power down to 50% re-
duces sample size by 63% compared with 90%
power, but only a gambler would take such a risk.
Few trials are performed with <80% power.
4. Type I error. One could choose options other than
the conventional 0.05. For instance, changing to
0.1 or 0.01 would make trial size around 19%
smaller and 42% bigger, respectively, but the
former falls short of conventional signiﬁcance and
the latter is not commonly chosen.
An important fact when determining trial size is to
recognize that statistical power dependsmainly on the
total number of patients in the trial experiencing the
primary event during follow-up. Thus, some trials are
event-driven, meaning that all patients are followed
until that calendar date when the required number of
events has occurred. Applying this logic, how many
events should a trial aim for? A useful approximate
formula is the following: one declares the hazard
ratio (R) (or risk ratio) for the alternative hypothesis
and its associated statistical power (1 b) (often 90% or
80%) and the 2-sided type I error (a) (usually 0.05).
Then, the total events required is calculated:
D ¼ ð1 þ RÞ
2
ð1  RÞ2  f ða; bÞ
where f ða; bÞ ¼

zb þ za =2
2
, which equates to 10.51
and 7.85 for 90% and 80% power, respectively, with
a ¼ 0.05. z is a standardized normal deviate.
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(i.e., a 30% relative risk reduction) with 80% power,
then 252 total primary events are required. A much
tougher challenge is to detect a hazard ratio of 0.85
(i.e., a 15% relative risk reduction) with 80% power
because this requires a total of 1,194 primary
events.
Figure 2 displays the power curves to assist the
reader in determining his or her own trial size
(required number of events) for any choice of hazard
ratio, with options for 90% and 80% power, as
desired.
It has been argued that all power calculations
enforce an arbitrary logic by focusing on a particular
alternative hypothesis. In practice, the trial statisti-
cian could produce extensive tabulations by varying
all 4 of the parameters that have been discussed, thus
guiding the investigators to a sensible trial size.
Overall, a concise logic, speciﬁed in both the trial
protocol and the publication’s methods section, helps
to instill conﬁdence that the trialists chose wisely
(and achieved) their target sample size. Of course,
“the bigger the better” is a crude maxim whereby the
larger the trial becomes, the greater the precision of
any treatment effect estimate (and the more likely are
the results to approximate “the truth”). This scientiﬁc
optimization always needs to be placed in perspective
alongside the need to keep the trial’s scale, duration,
and costs ﬁnite.CONCLUDING REMARKS
A sound knowledge of the essential issues in the
design of major randomized trials, as outlined in this
paper, is of importance to cardiologists and others
involved in trials research and their interpretation.
Although there are many details of relevance, the
essential elements of designing a worthwhile inves-
tigation include:
1. Identifying a valuable therapeutic concept worthy
of a major trial;
2. Focusing on the essentials of the trial protocol:
deﬁning exactly which patients, which treatment
comparison(s), and which primary (and secondary)
endpoints should be studied;
3. Ensuring that the trial provides a reliable (un-
biased) treatment comparison by appropriate
randomization, blinding, and quality delivery of
the protocol’s intent; and
4. Making the trial large enough so that it is
adequately powered to detect (or refute) any
treatment differences of clinical importance.
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